Literature DB >> 12605175

Trends in surgery for gastroesophageal reflux disease: the effect of laparoscopic surgery on utilization.

Samuel R G Finlayson1, John D Birkmeyer, William S Laycock.   

Abstract

BACKGROUND: In addition to substituting for open surgery, minimally invasive surgery may lower thresholds for intervention and thus increase overall utilization rates. The degree to which laparoscopy may have lowered the threshold for elective anti-reflux surgery is unknown.
METHODS: Using the Uniform Hospital Discharge Dataset and ICD-9 procedure and diagnosis codes, we identified all laparoscopic and open anti-reflux procedures performed on adults in Massachusetts, New Hampshire, and Vermont for each year from 1993 to 1998. We then examined secular trends and regional variation in the use of laparoscopic and open anti-reflux surgery.
RESULTS: The population-based rate of anti-reflux surgery more than doubled between 1993 (4.8 per 100,000) and 1998 (11.7 per 100,000). Laparoscopic anti-reflux procedures increased more than 6-fold between 1993 and 1998, from 1.2 to 8.9 procedures per 100,000 adults, with accompanying declines in overall length of stay and mortality. However, the number of open anti-reflux procedures decreased only modestly (22%) over this time period. In the year hospitals performed their first laparoscopic anti-reflux operation, procedure rates nearly tripled, on average, and then increased slowly in subsequent years. In 1997 and 1998, rates of anti-reflux surgery varied nearly 5-fold across hospital referral regions, ranging from 5.4 to 24.5 per 100,000.
CONCLUSIONS: With the growth of minimally invasive surgery, rates of anti-reflux surgery have increased substantially, with wide regional variation in intervention rates. Further research is needed to determine the appropriate threshold for surgical treatment in patients with gastroesophageal reflux.

Entities:  

Mesh:

Year:  2003        PMID: 12605175     DOI: 10.1067/msy.2003.13

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  8 in total

1.  Laparoscopic Nissen fundoplication: the "right posterior" approach.

Authors:  Attila Csendes; Patricio Burdiles; Owen Korn
Journal:  J Gastrointest Surg       Date:  2005 Sep-Oct       Impact factor: 3.452

2.  The rise and fall of antireflux surgery in the United States.

Authors:  Jonathan F Finks; Yongliang Wei; John D Birkmeyer
Journal:  Surg Endosc       Date:  2006-09-06       Impact factor: 4.584

3.  Laparoscopic cholecystectomy versus mini-laparotomy cholecystectomy: a meta-analysis of randomised control trials.

Authors:  Sanjay Purkayastha; Henry S Tilney; Panagiotis Georgiou; Thanos Athanasiou; Paris P Tekkis; Ara W Darzi
Journal:  Surg Endosc       Date:  2007-05-22       Impact factor: 4.584

4.  Trends in endoscopic sinus surgery rates in the Medicare population.

Authors:  Giridhar Venkatraman; Donald S Likosky; Weiping Zhou; Samuel R G Finlayson; David C Goodman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2010-05

5.  Increased morbidity and mortality in cardiac patients undergoing fundoplication.

Authors:  Heather L Short; Curtis Travers; Courtney McCracken; Mark L Wulkan; Matthew S Clifton; Mehul V Raval
Journal:  Pediatr Surg Int       Date:  2016-12-30       Impact factor: 1.827

6.  Introduction of laser technology and procedure use for benign prostatic hyperplasia: data from Florida.

Authors:  Florian R Schroeck; John M Hollingsworth; Samuel R Kaufman; Brent K Hollenbeck; John T Wei
Journal:  Urology       Date:  2012-07-27       Impact factor: 2.649

Review 7.  Whither surgery in the treatment of gastroesophageal reflux disease (GERD)?

Authors:  David R Urbach; Wendy J Ungar; Linda Rabeneck
Journal:  CMAJ       Date:  2004-01-20       Impact factor: 8.262

8.  Validation of ICD-9 Code 787.2 for identification of individuals with dysphagia from administrative databases.

Authors:  Marlís González-Fernández; Michael Gardyn; Shamolie Wyckoff; Paul K S Ky; Jeffrey B Palmer
Journal:  Dysphagia       Date:  2009-04-28       Impact factor: 3.438

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.